Clinical Trials Logo

Mantle Cell Lymphoma clinical trials

View clinical trials related to Mantle Cell Lymphoma.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT05868395 Not yet recruiting - Clinical trials for Mantle-cell Lymphoma

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Start date: May 24, 2023
Phase: Phase 2
Study type: Interventional

Polatuzumab, bendamustine and rituximab in patients with relapsed/ refractory mantle cell lymphoma

NCT ID: NCT05635162 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma

Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

ZEBRA
Start date: April 2024
Phase: Phase 2
Study type: Interventional

Phase II, multicentre, randomised, open-label study to assess the benefit of early intervention with fixed duration, time-limited zanubrutinib-rituximab in indolent mantle cell lymphoma (MCL)

NCT ID: NCT05004064 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma

Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

CARAMEL
Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II, single-arm, open-label, multicentre study of acalabrutinib and rituximab for elderly or frail patients with previously untreated mantle cell lymphoma.

NCT ID: NCT04279405 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Start date: April 2020
Phase: Phase 1
Study type: Interventional

Protocol YY-20394-007 is a phase1 open-label, single-arm, multi-centre study to assess the safety and efficacy of YY-20394 in participants with relapse and/or refractory B cell malignant hematological tumor. eligible participants will initiate oral therapy with YY-20394 at a starting dose of 80mg taken once per day. treatment with YY-20394 can continue in compliant participants as long as the study is still ongoing and the participants appear to benefiting from treatment with acceptable safety.

NCT ID: NCT03016988 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma

The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma

Start date: January 2017
Phase: Phase 2
Study type: Interventional

Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL) and shows poor survival. This study to evaluate the efficacy and safety of Bortezomib combined with Fludarabine and Cytarabine treatment in the naive and relapsed MCL who are not eligible for high dose therapy and transplantation.